中国肝脏病杂志（电子版）
中國肝髒病雜誌（電子版）
중국간장병잡지（전자판）
CHINESE JOURNAL OF LIVER DISEASES(ELECTRONIC VERSION)
2014年
3期
28-30
,共3页
纪民%蒲春文%李本科%迟坤%孙卫翔
紀民%蒲春文%李本科%遲坤%孫衛翔
기민%포춘문%리본과%지곤%손위상
肝肿瘤%放射学,介入性%治疗结果
肝腫瘤%放射學,介入性%治療結果
간종류%방사학,개입성%치료결과
Liver neoplasms%Radiology,interventional%Treatment outcome
目的：探讨肝动脉化疗栓塞术（TACE）在超声及数字血管造影机（DSA）监视下行经皮肝穿瘤内无水乙醇注射（PEI）治疗原发性肝癌（PLC）的安全性及疗效。方法选择57例PLC患者随机分为联合治疗组（TACE ＋ PEI）30例和对照组（单纯TACE）27例。联合治疗组在DSA下行TACE术后即刻在超声及DSA引导下细针PEI。对照组行常规TACE治疗。结果联合治疗组在超声及DSA引导下全部精准穿刺靶点，术中中等疼痛18例，无其他严重不良反应，其术后发热、肝肾功能、血常规、PT等指标与对照组比较，差异均无统计学意义（P均＞0.05），57例患者均无严重并发症出现。联合治疗组有效率为83.3%（25/30），对照组为55.6%（15/27）；联合治疗组1年生存率为86.7%，对照组为63%，两组比较差异均有统计学意义（P ＜0.05）。结论肝动脉化疗栓塞同时行PEI治疗PLC安全性较好，其1年生存率优于单纯TACE治疗者。
目的：探討肝動脈化療栓塞術（TACE）在超聲及數字血管造影機（DSA）鑑視下行經皮肝穿瘤內無水乙醇註射（PEI）治療原髮性肝癌（PLC）的安全性及療效。方法選擇57例PLC患者隨機分為聯閤治療組（TACE ＋ PEI）30例和對照組（單純TACE）27例。聯閤治療組在DSA下行TACE術後即刻在超聲及DSA引導下細針PEI。對照組行常規TACE治療。結果聯閤治療組在超聲及DSA引導下全部精準穿刺靶點，術中中等疼痛18例，無其他嚴重不良反應，其術後髮熱、肝腎功能、血常規、PT等指標與對照組比較，差異均無統計學意義（P均＞0.05），57例患者均無嚴重併髮癥齣現。聯閤治療組有效率為83.3%（25/30），對照組為55.6%（15/27）；聯閤治療組1年生存率為86.7%，對照組為63%，兩組比較差異均有統計學意義（P ＜0.05）。結論肝動脈化療栓塞同時行PEI治療PLC安全性較好，其1年生存率優于單純TACE治療者。
목적：탐토간동맥화료전새술（TACE）재초성급수자혈관조영궤（DSA）감시하행경피간천류내무수을순주사（PEI）치료원발성간암（PLC）적안전성급료효。방법선택57례PLC환자수궤분위연합치료조（TACE ＋ PEI）30례화대조조（단순TACE）27례。연합치료조재DSA하행TACE술후즉각재초성급DSA인도하세침PEI。대조조행상규TACE치료。결과연합치료조재초성급DSA인도하전부정준천자파점，술중중등동통18례，무기타엄중불량반응，기술후발열、간신공능、혈상규、PT등지표여대조조비교，차이균무통계학의의（P균＞0.05），57례환자균무엄중병발증출현。연합치료조유효솔위83.3%（25/30），대조조위55.6%（15/27）；연합치료조1년생존솔위86.7%，대조조위63%，량조비교차이균유통계학의의（P ＜0.05）。결론간동맥화료전새동시행PEI치료PLC안전성교호，기1년생존솔우우단순TACE치료자。
Objective To investigate the efficiency and safety of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection (PEI) in patients with primary liver cancer (PLC). Methods Total of 57 cases of PLC patients were divided into combination therapy group (TACE + PEI, 30 cases) and control group (TACE alone, 27 cases) randomly. Combination therapy group was treatment in DSA downward showed immediate with conventional ultrasound and DSA guided fine needle PEI. Control group was treatment by conventional TACE treat. Results No major complication occurred except for moderate pain in 18 cases in combination treatment group. No significant difference between combination therapy group and control group in terms of occurrence of postoperative fever, liver and kidney injury, blood test abnormalities, and abnormal prothrombin time (all P > 0.05). The overall response rate (complete response and partial response, CR + PR ) in the combination therapy group was 83.3% (25/30), whereas in control group, it was 55.6%(15/27). The 12-month survival rate for the combination therapy group was 86.7%, which was significantly higher than that in control group (63%) (P < 0.05). Conclusions Compared to TACE alone, combination of TACE and PEI demonstrated a better 12-month survival rate with similar safety profile in PLC patients.
